NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Iterum Therapeutics PLC (ITRM) Stock Analysis

Iterum Therapeutics PLC (ITRM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ITRM

$0.08

+$0.02 (+36.36%)

Last trade May 26, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ITRM with… →

ITRM Key Statistics

As of May 26, 2026
Trading
Open
$0.07
Previous Close
$0.06
Day's Range
0.05–0.08
52-Week Range
0.03–1.42
Volume
203.44K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
3.01
Valuation
Market Cap
$1.60M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.10
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.72
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−91.95%
Dividend and dates
Avg Volume
16.33M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ITRM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−77.61%
2025−79.57%

As of May 26, 2026.

ITRM Valuation vs Biotechnology Median

Median of 656 stocks
MetricITRMBiotechnology medianvs median
P/S ratio4.1015.260.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Iterum Therapeutics PLC (ITRM) carries a market capitalisation of $1.60M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 9 employees.

ITRM last closed at $0.08 on May 26, 2026. That is +$0.02 (+36.36%) against the previous close. Over the past 52 weeks the price has ranged from $0.03 to $1.42. The latest close sits 176.75% above that 52-week low.

Financial Health

Trailing twelve-month revenue on file is $390.00K. The reported profit margin is 0%. Earnings per share on a trailing basis come to −0.72.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 4.1. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The trailing one-year price return is −91.95%. The reported beta is 3.01. Daily returns over the trailing 1 year annualize to a volatility of 345.02%.

Growth & Income

No dividend is on file for ITRM.

The record holds one complete calendar year, 2025, which returned −79.57%. 2026 is still running; the price is −77.61% year to date.

Peer Comparison

Iterum Therapeutics PLC (ITRM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Iterum Therapeutics PLC ITRM $1.60M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Iterum Therapeutics PLC has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 26, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Iterum Therapeutics PLC

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Visit website →